Clinical outcomes with alpelisib (ALP) plus fulvestrant (FUL) after prior treatment (tx) with FUL in patients (pts) with advanced breast cancer (ABC): A real-world (RW) analysis.

被引：0
|
作者：
O'Shaughnessy, Joyce
Woeckel, Achim
Pistilli, Barbara
Hegg, Roberto
Vahdat, Linda T.
Vuina, Dragica
Asad, Zvk Parisa
Smith, Timothy W.
Kim, Julia
Krop, Ian
机构：
[1] Baylor Univ Med Ctr, Texas Oncol, US Oncol Network, Dallas, TX USA
[2] Univ Wurzburg, Wurzburg, Germany
[3] Inst Macerata, Macerata, Italy
[4] Univ Sao Paulo, Sao Paulo, SP, Brazil
[5] Dartmouth Canc Ctr, Lebanon, NH USA
[6] Novartis Oncol, Zagreb, Croatia
[7] Novartis Oncol, Basel, Switzerland
[8] Novartis Pharmaceut, E Hanover, NJ USA
[9] Genesis Res, Hoboken, NY USA
[10] Dana Farber Canc Inst, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1055
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Alpelisib (ALP) plus fulvestrant (FUL) in patients from Japan with advanced breast cancer: Subgroup analysis of SOLAR-1 trial
    Iwata, Hiroji
    Yamashita, Toshinari
    Inoue, Kenichi
    Takahashi, Masato
    Masuda, Norikazu
    Yamauchi, Teruo
    Yamamoto, Yutaka
    Takano, Toshimi
    Niikura, Naoki
    Nakayama, Takahiro
    Takashima, Seiki
    Matsumoto, Koji
    Sagara, Yasuaki
    Fujii, Takaaki
    Hattori, Toru
    Sekiguchi, Risa
    Wilke, Celine
    ANNALS OF ONCOLOGY, 2019, 30 : 80 - 80
  • [2] Efficacy of alpelisib (ALP) plus fulvestrant (FUL) with rational use of metformin (MET) in patients with HR+/HER2-advanced breast cancer (ABC).
    Filonenko, Daria
    Orlova, Rashida
    Gluzman, Mark
    Vakhitova, Almira
    Goryainova, Alla
    Grechukhina, Katerina
    Bykonya, Irina
    Zhukova, Lyudmila
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] Alpelisib (ALP) 1 fulvestrant (FUL) for advanced breast cancer (ABC): Results of the phase III SOLAR-1 trial
    Andre, F.
    Ciruelos, E. M.
    Rubovszky, G.
    Campone, M.
    Loibl, S.
    Rugo, H. S.
    Iwata, H.
    Conte, P.
    Mayer, I. A.
    Kaufman, B.
    Yamashita, T.
    Lu, Y. -S.
    Inoue, K.
    Takahashi, M.
    Papai, Z.
    Longin, A-S.
    Mills, D.
    Wilke, C.
    Hirawat, S.
    Juric, D.
    ANNALS OF ONCOLOGY, 2018, 29 : 709 - 709
  • [4] Long-term (LT) disease control in patients (pts) with hormone receptor-positive (HR+), PIK3CA-altered advanced breast cancer (ABC) treated with alpelisib (ALP) plus fulvestrant (FUL).
    Juric, Dejan
    Andre, Fabrice
    Panwar, Udaiveer
    Janku, Filip
    Lu, Yen-Shen
    Burris, Howard A., III
    Cruz Jurado, Josefina
    Papai, Zsuzsanna
    Stemmer, Salomon M.
    Tabernero, Josep
    Ahlgren, Johan
    Leheurteur, Marianne
    Lorenzo, Ines
    Jankovic, Dragana
    Quadt, Cornelia
    Hu, Huilin
    Chen, Xueying
    Rugo, Hope S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [5] Real-world effectiveness of alpelisib (ALP) plus fulvestrant (FUL) compared with standard treatment among patients (Pts) with hormone-receptor positive (HR plus ) human epidermal growth factor receptor-2 negative (HER2-) PIK3CA-mutated (Mut) advanced breast cancer (ABC)
    Turner, S.
    Chia, S. K. L.
    Kanakamedala, H.
    Hsu, W-C.
    Park, J.
    Chandiwana, D.
    Ridolfi, A.
    Yu, C-L.
    Zarate, J. P.
    Rugo, H. S.
    ANNALS OF ONCOLOGY, 2020, 31 : S366 - S366
  • [6] Real-world (rw) clinical outcomes on alpelisib (ALP) in patients (pts) with breast cancer (BC) and PIK3CA mutations (PIK3CAm).
    Rugo, Hope S.
    Raskina, Kira
    Schrock, Alexa Betzig
    Israel, Mason A.
    Sokol, Ethan
    Sivakumar, Smruthy
    Ward, Ashley
    Creeden, James
    Oxnard, Geoffrey R.
    McGregor, Kimberly
    Venstrom, Jeffrey Michael
    Tukachinsky, Hanna
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [7] Clinical outcomes with alpelisib (ALP) plus fulvestrant (FUL) in patients with HR-positive (HR+)/HER2-negative (HER2-) advanced breast cancer (ABC) with PIK3CA mutations (m) in routine practice at several Russian centers
    Zhukova, Lyudmila
    Filonenko, Daria
    Grechukhina, Katerina
    Stepanchencko, Margarita
    Orlova, Rashida
    Gluzman, Mark
    Vakhitova, Almira
    Goryainova, Alla
    Fedyanin, Mikhail
    Glazkova, Elena
    Stroyakovsky, Daniil
    Danilova, Anastasia
    Pokataev, Ilya
    Stativko, Olesia
    Andreyashkina, Irina
    Trotsenko, Ivan
    Khatkov, Igor
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] Antineoplastic (ANP) therapies (Tx) after alpelisib (ALP) or placebo (PBO) plus fulvestrant (FUL) in patients (Pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated (Mut) advanced breast cancer (ABC): An analysis from SOLAR-1
    Andre, F.
    Rugo, H. S.
    Juric, D.
    Rubovsky, G.
    Yamashita, T.
    Stemmer, S. M.
    Lu, Y- S.
    Miller, M. K.
    Lorenzo, I.
    Hu, H.
    Ciruelos, E. M.
    ANNALS OF ONCOLOGY, 2021, 32 : S498 - S499
  • [9] Alpelisib (ALP) plus fulvestrant (FUL) for patients with hormone receptor-positive (HR+), HER2-advanced breast cancer (ABC): Management and time course of key adverse events of special interest (AESIs) in SOLAR-1
    Rugo, H. S.
    Andre, F.
    Yamashita, T.
    Cerda, H.
    Toledano, I.
    Stemmer, S.
    Cruz Jurado, J.
    Juric, D.
    Mayer, I.
    Ciruelos, E. M.
    Iwata, H.
    Conte, P. F.
    Campone, M.
    Wilke, C.
    Mills, D.
    Lorenzo, I.
    Miller, M.
    Loibl, S.
    ANNALS OF ONCOLOGY, 2019, 30 : 112 - +
  • [10] Real-world (RW) treatment (tx) patterns and outcomes in patients (pts) from Taiwan and Singapore with intermediate and advanced hepatocellular carcinoma (HCC)
    Choo, S. P.
    Mhatre, S. K.
    Ferro, A.
    Machado, R.
    Liu, D. H-C.
    Irahara, N.
    Gaillard, V. E.
    Shao, Y-Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S1309 - S1310
12345